Core Insights - Immutep Limited's investigator-initiated EFTISARC-NEO Phase II trial has successfully met its primary endpoint, demonstrating a significant increase in tumour hyalinization/fibrosis in patients with resectable soft tissue sarcoma (STS) when treated with eftilagimod alfa (efti) combined with radiotherapy and KEYTRUDA® [1][7]. Company Overview - Immutep is a late-stage biotechnology company focused on developing innovative immunotherapies for cancer and autoimmune diseases, particularly leveraging the Lymphocyte Activation Gene-3 (LAG-3) pathway [7]. - The company is pioneering the understanding and advancement of therapeutics related to LAG-3, aiming to provide novel treatment options for patients and maximize shareholder value [7]. Trial Details - The EFTISARC-NEO trial showed a median of 50% tumour hyalinization/fibrosis in a preliminary analysis of 21 patients, significantly exceeding the prespecified median of 35% [3]. - The trial is primarily funded by a grant from the Polish government, with a total enrollment of 40 patients completed in January 2025 [3][4]. Medical Significance - Tumour hyalinization/fibrosis serves as an early surrogate endpoint linked to improved overall survival and recurrence-free survival in STS patients [2]. - STS is classified as an orphan disease with a high unmet medical need and poor prognosis, with an estimated 13,520 new cases and 5,420 deaths in the U.S. in 2025 [4]. Eftilagimod Alfa (efti) Profile - Efti is a proprietary soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity, enhancing the immune response against cancer [5]. - Efti is under evaluation for various solid tumours, including non-small cell lung cancer and head and neck squamous cell carcinoma, and has received Fast Track designation from the FDA for certain indications [6].

Core Insights - Super League has expanded its partnership with AdArcade to enhance revenue diversification through a patented mobile ad format that delivers three times higher engagement than standard playable ads [1][3] - The partnership allows Super League to provide brands and media agencies with a scalable, full-funnel playable solution, reaching 220 million monthly gamers in the US [1][3] Revenue Diversification Strategy - The expansion into mobile games is a key pillar of Super League's revenue diversification strategy, expected to account for 25% of the company's revenues in 2025 [3] - The company anticipates that the demographic of video game players will continue to grow, with projections indicating that three out of four individuals under 50 will play video games [3] Ad Performance Metrics - Native Playables, the interactive ads developed by AdArcade, achieve a return on ad spend (ROAS) as high as 13 times compared to standard playable ads [2][3] - The ads are designed to match the gameplay experience, leading to superior performance across key metrics [2][3] Audience Engagement - Native Playables target a broad audience, including Millennials, Gen X, Gen Z, and Gen Alpha, who engage with popular mobile games like Roblox, Minecraft, and Fortnite [4][7] - The partnership aims to effectively engage a multi-generational mobile gaming audience, enhancing brand visibility and consumer interaction [4][7] Operational Efficiency - The deployment of Native Playables can be completed in less than two weeks, with ad creation taking just hours due to AdArcade's automated system [3] - This efficiency allows brands to rapidly produce multiple playable ads tailored to specific demographic audiences [3]

Core Insights - NeuroPace has completed the primary endpoint analysis of the one-year data from the NAUTILUS study, which is the first clinical study evaluating neuromodulation therapy for idiopathic generalized epilepsy (IGE) [1][7] - The study demonstrated excellent safety outcomes, meeting the primary safety endpoint with a low rate of serious adverse events related to the device [2][3] - While the primary effectiveness endpoint did not reach statistical significance in the overall population, a significant response was observed in a subgroup of patients with lower baseline seizure frequency [3][6] Study Results - The NAUTILUS study met its primary 12-week post-implant safety endpoint, confirming the favorable safety profile of the RNS System [2][3] - Clinically relevant data showed median percent seizure reduction and responder rates that were numerically robust and clinically meaningful over the first year of treatment [4][6] - The study included 100 participants, with 87 undergoing implantation of the RNS Neurostimulator across 23 epilepsy centers in the US [7] Future Plans - NeuroPace plans to submit the full dataset to the FDA and for peer-reviewed publication, engaging in discussions regarding regulatory pathways based on the data [8] - The company aims to expand access to RNS therapy and is confident in the potential for future indication expansion into IGE [5][8] - The company reaffirms its full-year 2025 financial guidance, indicating a strong base business growing over 20% year over year [9][5]

Conference Call and Webcast on Wednesday, May 28, 2025, at 4:30 p.m. ETSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant prostate ca ...

Vadadustat clinical data on display for nephrologists and healthcare providersCAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it will present data at the 62nd European Renal Association (ERA) Congress on June 4-7, 2025, both virtually and live in Vienna. Akebia-supported presentations at ERA Congress 2025: A Win-Ratio Analysis of the Cardiovascu ...

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference ...

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock ConferenceDate: June 3, 2025Location: Chicago, ILFormat: Mana ...

Group 1 - Verizon's executive vice president and CEO for Verizon Consumer, Sowmyanarayan Sampath, will speak at the Bernstein Strategic Decisions Conference on May 29, 2025, at 8:00 a.m. ET, with a webcast available on the Investor Relations website [1] - Verizon generated revenues of $134.8 billion in 2024, highlighting its significant market presence and commitment to innovation [2] - The company serves millions of customers globally, including nearly all of the Fortune 500, focusing on mobility, reliable network connectivity, and security [2] Group 2 - Verizon's online media center provides access to news releases, stories, and media contacts, enhancing communication with stakeholders [3] - Media contacts for Verizon include Adi Wineland, who can be reached via email for inquiries [3]

RIMOUSKI, Quebec, May 27, 2025 (GLOBE NEWSWIRE) -- Puma Exploration Inc. (TSXV: PUMA) (“Puma”), announces that its subsidiary, Murray Brook Minerals Inc. (“MBM” or “Murray Brooks Minerals”) has closed a non-brokered offering consisting of 4,400,000 flow-through common shares (the "FT Shares") of MBM at a price of C$0.05 per FT Share for aggregate gross proceeds of $220,000 (the “FT Offering”). Following the FT Offering, Murray Brook Minerals has now 28,044,165 common shares issued and outstanding, with no w ...

Core Insights - Spectral AI's DeepView System has demonstrated a 95.3% overall accuracy in predicting burn healing potential, significantly outperforming traditional subjective assessments [1][2] - The technology has been recognized in the journal Burns, highlighting its clinical importance and transformative role in burn care [2] Company Overview - Spectral AI, Inc. is a Dallas-based predictive AI company focused on enhancing medical diagnostics for wound care, particularly for burn patients [3] - The DeepView System aims to provide objective and immediate assessments of burn wounds, facilitating faster and more accurate treatment decisions [3] - The company is committed to improving patient outcomes and reducing healthcare costs through its innovative technology [3] Clinical Significance - The study published in Burns represents the first multi-center evaluation of AI-enhanced multispectral imaging in burn assessment, showcasing the effectiveness of the DeepView System across various clinical settings [2] - The technology empowers clinicians with data-driven insights, improving decision-making regarding healing time and the need for surgical interventions [2] Industry Context - Burns is a prominent peer-reviewed medical journal dedicated to advancements in burn care and wound healing, serving as a critical platform for sharing innovative techniques and best practices [2]